These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 26458505)

  • 1. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    Kang X; Hu DY; Li CB; Ai ZS; Peng A
    Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.
    Sun Z; Fu Q; Cao L; Jin W; Cheng L; Li Z
    PLoS One; 2013; 8(1):e55124. PubMed ID: 23383076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhao SJ; Zhong ZS; Qi GX; Tian W
    Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy.
    Guru V; Fremes SE
    Clin Nephrol; 2004 Aug; 62(2):77-83. PubMed ID: 15356963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of sodium bicarbonate in preventing contrast-induced nephropathy in patients with pre-existing renal insufficiency: a meta-analysis.
    Zhang B; Liang L; Chen W; Liang C; Zhang S
    BMJ Open; 2015 Mar; 5(3):e006989. PubMed ID: 25783425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the impact of N-acetylcysteine on contrast nephropathy.
    Pannu N; Manns B; Lee H; Tonelli M
    Kidney Int; 2004 Apr; 65(4):1366-74. PubMed ID: 15086476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
    Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of N--acetylcysteine in the prevention of contrast-induced nephropathy in patients undergoing peripheral angiography: a structured review and meta-analysis.
    O'Sullivan S; Healy DA; Moloney MC; Grace PA; Walsh SR
    Angiology; 2013 Nov; 64(8):576-82. PubMed ID: 23188834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis.
    Navaneethan SD; Singh S; Appasamy S; Wing RE; Sehgal AR
    Am J Kidney Dis; 2009 Apr; 53(4):617-27. PubMed ID: 19027212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Prevention Strategies for Contrast-Induced Nephropathy: A Systematic Review and Meta-analysis.
    Subramaniam RM; Suarez-Cuervo C; Wilson RF; Turban S; Zhang A; Sherrod C; Aboagye J; Eng J; Choi MJ; Hutfless S; Bass EB
    Ann Intern Med; 2016 Mar; 164(6):406-16. PubMed ID: 26830221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of N-acetylcysteine on the incidence of contrast-induced kidney injury: A systematic review and trial sequential analysis.
    Wang N; Qian P; Kumar S; Yan TD; Phan K
    Int J Cardiol; 2016 Apr; 209():319-27. PubMed ID: 26922293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
    Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
    Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.
    Ma WQ; Zhao Y; Wang Y; Han XQ; Zhu Y; Liu NF
    Int Urol Nephrol; 2018 Jun; 50(6):1085-1095. PubMed ID: 29404930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.